00:00
00:00
00:00
ValiRx - ValiSeek Clinical Development Update

Since its last clinical update on 8 March 2017, ValiSeek is pleased to report continued progress of the trial of VAL401 in the treatment of non-small cell lung cancer. ValiSeek has decided now to cease enrolling new participants and will continue to measure the outcomes of those patients still on trial, while commencing analysis of the results to date.

Suzanne Dilly
CEO, ValiSeek Limited

Company Events - VALIRX PLC